● Recruiting

Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

Condition: Opioid-induced Constipation · Sponsor: BioDelivery Sciences International

PhaseN/A

Planned participants34532

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The research objective is to characterize the risk of a major adverse cardiovascular event (MACE) among new users of naldemedine versus new users of lubiprostone and new users of naloxegol as comparator opioid induced constipation (OIC) medications.

This description comes directly from the study's public registry record.

Talk to the study team

Todd Kunkel · 913-940-1789 · tkunkel@bdsi.com

Tom Smith · tsmith@bdsi.com

Always discuss trial participation with your own doctor first.

Locations (1)

Research Site

Wilmington, Delaware, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03720613